Role of long non-coding RNAs in lymphoma: A systematic review and clinical perspectives.

Affiliation

Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, 250021, China; School of Medicine, Shandong University, Jinan, Shandong, 250012, China; Shandong Provincial Engineering Research Center of Lymphoma, Jinan, Shandong, 250021, China; Key Laboratory for Kidney Regeneration of Shandong Province, Jinan, Shandong, 250021, China. Electronic address: [Email]

Abstract

Long non-coding RNAs (lncRNAs), are over 200 nucleotides in length, and they rarely act as templates for protein synthesis. Mounting studies have shown that lncRNAs play a crucial regulatory role in various processes that sustain life, such as epigenetic regulation, cell cycle control, splicing, and post-transcriptional regulation. LncRNAs were aberrantly expressed in most hematological malignancies including lymphoma, participating in tumor suppression or promoting oncogenesis and modulating key genes in different pathways. The specific expression patterns of lncRNAs in lymphoma make them good candidates to be used as diagnostic biomarkers or as therapeutic targets. LncRNAs can be targeted by multiple approaches including nucleic acid therapeutics, CRISPR/Cas genome editing techniques, small molecule inhibitors, and gene therapy. Efforts are made to develop therapeutic strategies aimed at targeting lncRNAs, but there are still some avenues to be covered before they can be applied to the clinical treatment of lymphoma.

Keywords

Biomarker,Long non-coding RNA,Lymphoma,Oncogenesis,Therapeutic target,Tumor suppression,

OUR Recent Articles